검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization) Roche / Genentech·Advanced Hepatocellular Carcinoma … 3 trials |
|---|---|
Overview Program | Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Advanced Hepatocellular Carcinoma (HCC), |
Overview Indication | Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Biomarker | biomarkers for regimen selection, de-escalation criteria, optimal sequencing, and integration with LRT or per |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | The following outcomes were retrieved: overall survival (OS), radiologic tumor response, progression-free survival, technical adverse events related to TARE, and toxicity based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Combination Immunotherapy and Yttrium-90 Radioembolization in Hepatocellular Carcinoma: Biological Rationale, Clinical Evidence, and Future Directions.. Background/Objectives : The integration of locoregional and systemic therapies represents a promising strategy in hepatocellular carcinoma (HCC). Yttrium-90 (Y-90) radioembolization provides durable local tumor control, while immune checkpoint inh… |
Clinical Data Tier / Score | A · 5 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | atezolizumab (Tecentriq, Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization) Roche / Genentech·Advanced Hepatocellular Carcinoma … 3 trials |
|---|---|
Overview Program | Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Advanced Hepatocellular Carcinoma (HCC), |
Overview Indication | Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Biomarker | biomarkers for regimen selection, de-escalation criteria, optimal sequencing, and integration with LRT or per |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | The following outcomes were retrieved: overall survival (OS), radiologic tumor response, progression-free survival, technical adverse events related to TARE, and toxicity based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Combination Immunotherapy and Yttrium-90 Radioembolization in Hepatocellular Carcinoma: Biological Rationale, Clinical Evidence, and Future Directions.. Background/Objectives : The integration of locoregional and systemic therapies represents a promising strategy in hepatocellular carcinoma (HCC). Yttrium-90 (Y-90) radioembolization provides durable local tumor control, while immune checkpoint inh… |
Clinical Data Tier / Score | A · 5 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교